Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Future: Dedicated NASH Phase 3 Trial Expected Timeline IF Retatrutide Approved for Obesity/Diabetes (2028): 2027-2028: Dedicated NASH Phase 3 trial begins Population: Biopsy-confirmed NASH with fibrosis (F1-F3) Primary endpoint: NASH resolution without worsening fibrosis Baseline and Week 72-96 liver biopsies Duration: 18-24 months minimum 2029-2030: Trial results published 2030-2031: FDA approval decision for NASH indication Why This Matters Current Reality: Only one FDA-approved medication exists for NASH resmetirom (Rezdiffra), approved March 2024
In addition to its diabetes management benefits, Semaglutide GLP-1 has garnered attention for its potential in weight management
Copyright The Author(s) 2021
Consult healthcare professionals before use, and stay updated on evolving regulations and studies
Healthcare professionals have been advised to remain vigilant for signs and symptoms of acute pancreatitis in patients treated with GLP-1 and GLP-1/GIP receptor agonists
US$ 26.23
US$ 22.19
US$ 27.54
US$ 29.13
US$ 23.09
US$ 23.44
US$ 20.40
